TAXA BiotechnologiesSummer 2014Inactive☆Watch⊞Compare

TAXA Biotechnologies is one of 233 Biotech companies tracked from San Francisco, CA, USA, on record since 2014. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

We enable cheaper, faster, and better genetic engineering of plants.…

The TAXA platform has been specifically designed to enable anyone to perform metabolic engineering of plants without stepping into a lab. We provide access to protein engineering, DNA assembly, transient experiments and stable transformation as a service. The best thing is that anything "Powered by TAXA" is designed to be free from expensive regulatory approval, meaning the products are available for sale or distribution to consumers in the United States immediately after they are developed. For a detailed list of the experiments which can be run on our platform please see the Services page. Our vision is a world where bio-engineering is as easy and commonplace as mobile application development is today. Game-changing technologies, like genetic engineering, should not be the exclusive preserve of large corporations and a wealthy elite. Democratizing the tools of creation enables anyone, anywhere, to genetically engineer plants and will unleash a wave of creativity to power an environment where ultimately what we create is limited only by our imagination. The TAXA platform is our next step in the realization of that dream We are also the team behind the first synthetic biology crowdfunding project, raising $484k on Kickstarter to make real glowing plants: www.glowingplant.com

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 67% of sector peers (real $). Modeled value above 67% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

TAXA Biotechnologies is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where TAXA Biotechnologies sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at TAXA Biotechnologies, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.